Friday, July 10, 2026

pharma · Nasopharyngeal Carcinoma · Hepatocellular Carcinoma

Chinese Academy of

Chinese Academy of is a pharma organization headquartered in TAIZHOU, CN. Primary therapeutic focus areas include Nasopharyngeal Carcinoma, Hepatocellular Carcinoma, COVID-19, Breast Cancer, Coronary Artery Disease. Nova

China, TAIZHOU, CN HQ
170 Employees
NMPA registrant Type
Company details
Status
Public
HQ
China, TAIZHOU, CN
Employees
170
Programs
1328
Drugs
711
Patents
335
Clinical program

Surgery combined with Target-reduction intensity-modulated radiotherapy

Unknown · other · Nasopharyngeal Carcinoma

Surgery combined with Target-reduction intensity-modulated radiotherapy for Nasopharyngeal Carcinoma is a Unknown program (other) at Xiyuan Hospital of China Academy of Chinese Medical Sciences with 1 ClinicalTrials.gov record(s).

Internal code SYSUCC-CMY-20240221

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase
Unknown
Modality
other
Indication
Nasopharyngeal Carcinoma
Status
active
Trials
1

Clinical trials